New hope for lung cancer patients: drug study aims to keep cancer at bay

NCT ID NCT07161388

Summary

This study is observing how well a drug called durvalumab works to help control limited stage small-cell lung cancer after patients finish standard chemoradiation treatment. It will follow 200 patients in China who have not gotten worse after their initial treatment. The goal is to see if adding durvalumab helps keep the cancer from progressing longer and is safe in real-world hospital settings.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    NOT_YET_RECRUITING

    Beijing, China

  • Research Site

    RECRUITING

    Beijing, China

  • Research Site

    NOT_YET_RECRUITING

    Cangzhou, China

  • Research Site

    RECRUITING

    Dongguan, China

  • Research Site

    RECRUITING

    Fuzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    RECRUITING

    Huzhou, China

  • Research Site

    RECRUITING

    Jinan, 250117, China

  • Research Site

    RECRUITING

    Jinan, China

  • Research Site

    NOT_YET_RECRUITING

    Jinzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Nanjing, China

  • Research Site

    RECRUITING

    Nanning, China

  • Research Site

    RECRUITING

    Ningbo, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, China

  • Research Site

    NOT_YET_RECRUITING

    Shenzhen, China

  • Research Site

    RECRUITING

    Shijiazhuang, China

  • Research Site

    RECRUITING

    Taiyuan, China

  • Research Site

    RECRUITING

    Tianjing, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Wuhan, China

  • Research Site

    NOT_YET_RECRUITING

    Wuxi, China

  • Research Site

    RECRUITING

    Yangzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Zhengzhou, China

  • Research Site

    RECRUITING

    Zhengzhou, China

Conditions

Explore the condition pages connected to this study.